(Q51774995)

12 April 2018

title

Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. (English)

1 reference

12 April 2018

0 references

1 reference

Xueying Sun

13

0 references

Hongchi Jiang

object named as

Hongchi Jiang

10

0 references

author name string

Xue-Pu Sun

1

1 reference

12 April 2018

Xuesong Dong

2

1 reference

12 April 2018

Lele Lin

3

1 reference

12 April 2018

Xian Jiang

4

1 reference

12 April 2018

Zheng Wei

5

1 reference

12 April 2018

Bo Zhai

6

1 reference

12 April 2018

Bo Sun

7

1 reference

12 April 2018

Qiang Zhang

8

1 reference

12 April 2018

Xiaolong Wang

9

1 reference

12 April 2018

Geoffrey W Krissansen

11

1 reference

12 April 2018

Haiquan Qiao

12

1 reference

12 April 2018

language of work or name

English

0 references

publication date

18 November 2013

1 reference

12 April 2018

published in

FEBS Journal

1 reference

12 April 2018

volume

281

1 reference

12 April 2018

issue

1

1 reference

12 April 2018

page(s)

115-128

1 reference

12 April 2018

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Mechanisms of resistance to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Targeting survivin in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Angiopoietin2 enhances doxorubin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

The role of hypoxia-inducible factors in tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

HIF-1 and HIF-2 transcription factors--similar but not identical

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Hypoxia inducible factor-1α-mediated activation of survivin in cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

AKT as locus of cancer multidrug resistance and fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Regulation of survivin by PI3K/Akt/p70S6K1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Thimerosal-induced apoptosis in mouse C2C12 myoblast cells occurs through suppression of the PI3K/Akt/survivin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Targeting hypoxia in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Distinct biological roles for the akt family in mammary tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.12577

21 January 2018

Identifiers

DOI

10.1111/FEBS.12577

1 reference

12 April 2018

PubMed ID

24165223

1 reference

12 April 2018